OJRA  Vol.4 No.1 , February 2014
Reduced Locomotor Activity Correlates with Increased Severity of Arthritis in a Mouse Model of Antibody-Induced Arthritis
Abstract: Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial hyperplasia and progressive cartilage and bone destruction that leads to a substantial loss of general functions and/or a decline in physical activities such as walking speed in humans. The K/BxN serum transfer arthritis in mice shares many immunological and pathological features with human RA. Very few studies are available in mice that investigate the changes in physical activity in relation to arthritis development. In this study we investigate the effect of arthritis on the locomotor activity of mice during K/BxN sera transfer arthritis. Methods: Arthritis was induced in Balb/c mice by injecting intraperitoneally with 200 μl of K/BxN sera; Balb/c mice injected with phosphate buffered saline (PBS) served as control. Progress of arthritis was estimated by daily measurements of joint thickness. Each mouse’s locomotor activity (travel distance and travel time) was assessed every day for duration of 20 minute period using the SmartCageTM platform. Data were analyzed using the SmartCageTM analysis software (CageScoreTM). Results: Arthritic Balb/c mice showed a reduction in distance covered and travel speed when compared to arthritis-free, control Balb/c mice. Maximum decline in locomotor activity was observed during the peak period of the disease and correlated to the increase in joint thickness in the arthritic mice. Conclusion: This report demonstrates that measuring locomotor activity of mice during progression of K/BxN sera-induced arthritis using the SmartCageTM platform offers a quantitative method to assess physical activity in mice during arthritis.
Cite this paper: N. Rajasekaran, R. Tran, C. Pascual, X. Xie and E. Mellins, "Reduced Locomotor Activity Correlates with Increased Severity of Arthritis in a Mouse Model of Antibody-Induced Arthritis," Open Journal of Rheumatology and Autoimmune Diseases, Vol. 4 No. 1, 2014, pp. 62-68. doi: 10.4236/ojra.2014.41010.

[1]   R. C. Lawrence, C. G. Helmick, F. C. Arnett, R. A. Deyo, D. T. Felson, E. H. Giannini, S. P. Heyse, R. Hirsch, M. C. Hochberg, G. G. Hunder, et al., “Estimates of the Prevalence of Arthritis and Selected Musculoskeletal Disorders in the United States,” Arthritis & Rheumatism, Vol. 41, No. 5, 1998, pp. 778-799.<778::AID-ART4>3.0.CO;2-V

[2]   G. Plasqui, “The Role of Physical Activity in Rheumatoid Arthritis,” Physiology & Behavior, Vol. 94, No. 2, 2008, pp. 270-275.

[3]   M. Tierney, A. Fraser and N. Kennedy, “Physical Activity in Rheumatoid Arthritis: A Systematic Review,” Journal of Physical Activity & Health, Vol. 9, No. 7, 2012, pp. 1036-1048.

[4]   C. L. Backman, “Employment and Work Disability in Rheumatoid Arthritis,” Current Opinion in Rheumatology, Vol. 16, No. 2, 2004, pp. 148-152.

[5]   R. Roubenoff, J. Walsmith, N. Lundgren, L. Snydman, G. J. Dolnikowski and S. Roberts, “Low Physical Activity Reduces Total Energy Expenditure in Women with Rheumatoid Arthritis: Implications for Dietary Intake Recommendations,” American Journal of Clinical Nutrition, Vol. 76, No. 4, 2002, pp. 774-779.

[6]   L. Hagfors, K. Westerterp, L. Skoldstam and G. Johansson, “Validity of Reported Energy Expenditure and Reported Intake of Energy, Protein, Sodium and Potassium in Rheumatoid Arthritis Patients in a Dietary Intervention Study,” European Journal of Clinical Nutrition, Vol. 59, 2005, pp. 238-245.

[7]   S. R. Piva, G. J. Almeida and M. C. Wasko, “Association of Physical Function and Physical Activity in Women with Rheumatoid Arthritis,” Arthritis Care & Research (Hoboken), Vol. 62, No. 8, 2010, pp. 1144-1151.

[8]   X. Li, M. A. Gignac and A. H. Anis, “The Indirect Costs of Arthritis Resulting from Unemployment, Reduced Performance, and Occupational Changes While at Work,” Medical Care, Vol. 44, No. 4, 2006, pp. 304-310.

[9]   N. Kennedy, F. Keogan, M. Fitzpatrick, G. Cussen and L. Wallace, “Characteristics of Patients with Rheumatoid Arthritis Presenting for Physiotherapy Management: A Multicentre Study,” Musculoskeletal Care, Vol. 5, No. 1, 2007, pp. 20-35.

[10]   D. L. Asquith, A. M. Miller, I. B. McInnes and F. Y. Liew, “Animal Models of Rheumatoid Arthritis,” European Journal of Immunology, Vol. 39, No. 8, 2009, pp. 2040-2044.

[11]   C. A. Christianson, M. Corr, G. S. Firestein, A. Mobargha, T. L. Yaksh and C. I. Svensson, “Characterization of the Acute and Persistent Pain State Present in K/BxN Serum Transfer Arthritis,” Pain, Vol. 151, No. 2, 2010, pp. 394-403.

[12]   A. Hartog, J. Hulsman and J. Garssen, “Locomotion and Muscle Mass Measures in a Murine Model of Collagen-Induced Arthritis,” BMC Musculoskeletal Disorders, Vol. 10, No. 1, 2009, p. 59.

[13]   D. Frommholz and H. Illges, “Maximal Locomotor Depression Follows Maximal Ankle Swelling during the Progression of Arthritis in K/BxN Mice,” Rheumatology International, Vol. 32, No. 12, 2012, pp. 3999-4003.

[14]   J. Vincelette, Y. Xu, L. N. Zhang, C. J. Schaefer, R. Vergona, M. E. Sullivan, T. G. Hampton and Y. X. Wang, “Gait Analysis in a Murine Model of Collagen-Induced Arthritis,” Arthritis Research and Therapy, Vol. 9, No. 6, 2007, p. R123.

[15]   L. Mandik-Nayak and P. M. Allen, “Initiation of an Autoimmune Response: Insights from a Transgenic Model of Rheumatoid Arthritis,” Immunologic Research, Vol. 32, No. 1-3, 2005, pp. 5-13.

[16]   B. T. Wipke, Z. Wang, W. Nagengast, D. E. Reichert and P. M. Allen, “Staging the Initiation of Autoantibody-Induced Arthritis: A Critical Role for Immune Complexes,” Journal of Immunology, Vol. 172, No. 12, 2004, pp. 7694-7702.

[17]   B. T. Wipke, Z. Wang, J. Kim, T. J. McCarthy and P. M. Allen, “Dynamic Visualization of a Joint-Specific Auto-immune Response through Positron Emission Tomography,” Nature Immunology, Vol. 3, No. 4, 2002, pp. 366- 372.

[18]   H. Ji, A. Pettit, K. Ohmura, A. Ortiz-Lopez, V. Duchatelle, C. Degott, E. Gravallese, D. Mathis and C. Benoist, “Critical Roles for Interleukin 1 and Tumor Necrosis Factor Alpha in Antibody-Induced Arthritis,” Journal of Experimental Medicine, Vol. 196, No. 1, 2002, pp. 77-85.

[19]   T. V. Khroyan, J. Zhang, L. Yang, B. Zou, J. Xie, C. Pascual, A. Malik, N. T. Zaveri, J. Vazquez, W. Polgar, et al., “Rodent Motor and Neuropsychological Behaviour Measured in Home Cages Using the Integrated Modular Platform SmartCage,” Clinical and Experimental Pharmacology and Physiology, Vol. 39, No. 7, 2012, pp. 614-622.

[20]   V. Kouskoff, A. S. Korganow, V. Duchatelle, C. Degott, C. Benoist and D. Mathis, “Organ-Specific Disease Provoked by Systemic Autoimmunity,” Cell, Vol. 87, No. 5, 1996, pp. 811-822.

[21]   S. U. Simjee, H. Jawed, J. Quadri and S. A. Saeed, “Quantitative Gait Analysis as a Method to Assess Mechanical Hyperalgesia Modulated by Disease-Modifying Antirheumatoid Drugs in the Adjuvant-Induced Arthritic Rat,” Arthritis Research & Therapy, Vol. 9, No. 5, 2007, p. R91.

[22]   R. Dubbeldam, A. V. Nene, J. H. Buurke, C. G. Groothuis-Oudshoorn, H. Baan, K. W. Drossaers-Bakker, M. A. van de Laar and H. Hermens, “Foot and Ankle Joint Kinematics in Rheumatoid Arthritis Cannot Only Be Explained by Alteration in Walking Speed,” Gait Posture, Vol. 33, No. 3, 2011, pp. 390-395.

[23]   D. E. Turner, P. S. Helliwell, P. Emery and J. Woodburn, “The Impact of Rheumatoid Arthritis on Foot Function in the Early Stages of Disease: A Clinical Case Series,” BMC Musculoskeletal Disorders, Vol. 7, No. 1, 2006, p. 102.

[24]   M. van der Leeden, M. Steultjens, J. H. Dekker, A. P. Prins and J. Dekker, “The Relationship of Disease Duration to Foot Function, Pain and Disability in Rheumatoid Arthritis Patients with Foot Complaints,” Clinical and Experimental Rheumatology, Vol. 25, No. 2, 2007, pp. 275-280.

[25]   M. Yamada, T. Aoyama, S. Mori, S. Nishiguchi, K. Okamoto, T. Ito, S. Muto, T. Ishihara, H. Yoshitomi and H. Ito, “Objective Assessment of Abnormal Gait in Patients with Rheumatoid Arthritis Using a Smartphone,” Rheumatology International, Vol. 32, No. 12, 2012, pp. 3869-3874.

[26]   N. Miyamoto, M. Senda, M. Hamada, Y. Katayama, A. Kinosita, K. Uchida and H. Inoue, “Talonavicular Joint Abnormalities and Walking Ability of Patients with Rheumatoid Arthritis,” Acta Medica Okayama, Vol. 58, No. 2, 2004, pp. 85-90.

[27]   E. T. Jernberg, P. Simkin, M. Kravette, P. Lowe and G. Gardner, “The Posterior Tibial Tendon and the Tarsal Sinus in Rheumatoid Flat Foot: Magnetic Resonance Imaging of 40 Feet,” Journal of Rheumatology, Vol. 26, No. 2, 1999, pp. 289-293.

[28]   C. I. Svensson, “Interleukin-6: A Local Pain Trigger?” Arthritis Research and Therapy, Vol. 12, No. 5, 2010, p. 145.

[29]   S. H. Ferreira, B. B. Lorenzetti, A. F. Bristow and S. Poole, “Interleukin-1 Beta as a Potent Hyperalgesic Agent Antagonized by a Tripeptide Analogue,” Nature, Vol. 334, No. 6184, 1988, pp. 698-700.

[30]   C. Sommer, S. Petrausch, T. Lindenlaub and K. V. Toyka, “Neutralizing Antibodies to Interleukin 1-Receptor Reduce Pain Associated Behavior in Mice with Experimental Neuropathy,” Neuroscience Letters, Vol. 270, No. 1, 1999, pp. 25-28.

[31]   S. Y. Al-Okbi, “Nutraceuticals of Anti-Inflammatory Activity as Complementary Therapy for Rheumatoid Arthritis,” Toxicology and Industrial Health, 2012.

[32]   L. G. Darlington and N. W. Ramsey, “Review of Dietary Therapy for Rheumatoid Arthritis,” Comprehensive Therapy, Vol. 20, 1994, pp. 490-494.

[33]   L. G. Darlington and T. W. Stone, “Antioxidants and Fatty Acids in the Amelioration of Rheumatoid Arthritis and Related Disorders,” British Journal of Nutrition, Vol. 85, No. 3, 2001, pp. 251-269.

[34]   E. A. Miles and P. C. Calder, “Influence of Marine n-3 Polyunsaturated Fatty Acids on Immune Function and a Systematic Review of Their Effects on Clinical Outcomes in Rheumatoid Arthritis,” British Journal of Nutrition, Vol. 107, Suppl. 2, 2012, pp. S171-184.